Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of “Moderate Buy” from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $28.28.

KURA has been the subject of a number of research analyst reports. Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a report on Wednesday, February 28th. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, April 15th. JMP Securities upped their price target on Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a report on Wednesday, January 31st. Finally, HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Monday, April 22nd.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Signaturefd LLC raised its stake in shares of Kura Oncology by 40.4% in the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after purchasing an additional 1,449 shares in the last quarter. Pale Fire Capital SE bought a new stake in Kura Oncology in the third quarter valued at $92,000. E Fund Management Co. Ltd. grew its position in Kura Oncology by 12.2% in the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after acquiring an additional 1,301 shares during the period. AXQ Capital LP bought a new stake in Kura Oncology in the third quarter valued at $118,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Kura Oncology by 352.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock valued at $124,000 after acquiring an additional 6,692 shares during the period.

Kura Oncology Stock Down 2.2 %

Shares of KURA stock opened at $19.62 on Wednesday. Kura Oncology has a 12 month low of $7.41 and a 12 month high of $24.17. The firm has a market cap of $1.49 billion, a PE ratio of -9.43 and a beta of 0.85. The stock has a 50 day moving average of $20.62 and a 200-day moving average of $15.79. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. During the same period last year, the business earned ($0.49) EPS. On average, equities analysts predict that Kura Oncology will post -2.35 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.